Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

Research Capital likes Theralase data update; sees FDA breakthrough filing soon

Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given the “strong data that has...

May 31, 2023

Developments

Glyscend posts positive topline Phase 2a results for Type 2 diabetes and obesity

Closely-held Glyscend Therapeutics reported that Phase 1 and Phase 2a clinical trials demonstrated that the novel mechanism of its lead candidate, GLY-200, offers significant and clinically relevant reductions in...

May 31, 2023

Developments

IntelGenx unveils short-term commercial objectives

IntelGenx (TSX:IGX; OTCQB:IGXT) unveiled a plan focussed on near-term revenue generation. “There is no question in my mind that IntelGenx has great science, services, assets, and people,”Dwight Gorham, the company’s...

May 31, 2023

Developments

BioLight, Alexion to explore natural tears for diagnosis of retinal diseases

BioLight (TASE:BOLT) signed a research collaboration agreement with Alexion, a rare disease unit of AstraZeneca, to explore a potentially ground-breaking technology that utilizes natural tears for the potential...

May 30, 2023

Markets

SVB ups Elevation Oncology to OP; PT to $8 on clinical update

SVB Securities upgraded Elevation Oncology (NASDAQ:ELEV) to “outperform” from “market perform” and raised its price target to $8 from $5, following the abstract release for EO-3021 (Claudin 18.2) ahead of ASCO. “This is...

May 30, 2023

Developments

GEN highlights iBio pivot to precision antibody immunotherapies

Genetic Engineering & Biotechnology News (GEN), in a feature article, outlines iBio’s (NYSE American:IBIO) transition from a contract development and manufacturing organization and cGMP biologics manufacturer to a...

May 30, 2023

Developments

Profound to reveal interim 5-year TACT follow-up data during June 6th webinar

Profound Medical (NASDAQ:PROF; TSX:PRN) will unveil interim five-year follow-up data from its TACT (TULSA-PRO ablation clinical trial) pivotal study at a live webinar event it is hosting on June 6 at 6 pm ET. The...

May 30, 2023

Markets

Stifel ups eFFECTOR to buy; PT to $7 on revaluating breast cancer

Stifel upgraded eFFECTOR Therapeutics (NASDAQ:EFTR) to “buy” from “hold” and raised its price target to $7 from $1.30, saying the “zotatifin combo is emerging as an active and underappreciated asset in breast cancer.”...

May 26, 2023

Executive Moves

Theralase names Roger DuMoulin-White as president and CEO

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) appointed Roger DuMoulin-White as president and CEO, succeeding Arkady Mandel, M.D., Ph.D., as interim CEO. Dr. Mandel will continue as CSO and a director. Mr. DuMoulin...

May 25, 2023

Developments

Hepion to highlight AI-POWR at medical conference

Hepion Pharmaceuticals (NASDAQ:HEPA) will outline the integration of its artificial intelligence and machine learning platform, AI-POWR, into all aspects of its clinical pharmacological programs at the 2023 Canadian...

May 25, 2023

Developments

Pyxis Oncology to acquire Apexigen

Pyxis Oncology (NASDAQ:PYXS) agreed to acquire Apexigen (NASDAQ:APGN) in an all-stock transaction for an implied value of 64 cents per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares...

May 24, 2023

Developments

Wave Life flunks Phase 1b/2a study in ALS and dementia

Wave Life Sciences’ (NASDAQ:WVE) drug candidate, WVE-004, did not show clinical benefit, compared with placebo, in the Phase 1b/2a FOCUS-C9 study as an investigational treatment for C9orf72-associated amyotrophic...

May 23, 2023

Research Capital likes Theralase data update; sees FDA breakthrough filing soon

Glyscend posts positive topline Phase 2a results for Type 2 diabetes and obesity

IntelGenx unveils short-term commercial objectives

BioLight, Alexion to explore natural tears for diagnosis of retinal diseases

SVB ups Elevation Oncology to OP; PT to $8 on clinical update

GEN highlights iBio pivot to precision antibody immunotherapies

Profound to reveal interim 5-year TACT follow-up data during June 6th webinar

Stifel ups eFFECTOR to buy; PT to $7 on revaluating breast cancer

Theralase names Roger DuMoulin-White as president and CEO

Hepion to highlight AI-POWR at medical conference

Pyxis Oncology to acquire Apexigen

Wave Life flunks Phase 1b/2a study in ALS and dementia

General

More